XCUR

+ Watchlist + Portfolio

Exicure, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $1.45
52-Week Range: $1.18 – $9.48
Market Cap: $8.51M
P/E (TTM): —
EPS (TTM): -1.31
Dividend Yield: —

Advanced Metrics

Price/Book: 3.95
PEG Ratio: —
Return on Equity: -145.16%
Return on Assets: -32.51%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 0.79
Debt/Equity: 0.01
Total Debt: $22.00K
Free Cash Flow: $-3.88M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $5.39M

XCUR Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$28.83M	$0.00	$500.00K	$0.00
Research & Development	$19.77M	$1.42M	$0.00	$3.29M
Selling, General & Admin	$10.89M	$11.71M	$5.45M	$6.83M
Operating Expenses	$30.66M	$13.14M	$5.45M	$10.12M
Operating Income	-$1.83M	-$13.14M	-$4.95M	-$10.12M
EBITDA	$78.00K	-$15.54M	-$8.85M	-$5.12M
Pretax Income	-$2.37M	-$16.91M	-$9.69M	-$5.58M
Income Tax	$209.00K	$0.00	$8.00K	-$634.00K
Net Income	-$2.58M	-$16.91M	-$9.70M	-$4.95M
Diluted EPS	-2.80	-10.55	-4.75	-0.79
Diluted Shares	923894	1.60M	2.04M	6.30M

XCUR Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$8.58M	$816.00K	$12.51M	$3.75M
Receivables	$111.00K	$250.00K	$558.00K	$58.00K
Current Assets	$10.05M	$2.02M	$13.67M	$4.62M
Total Assets	$23.33M	$11.58M	$15.06M	$14.04M
Current Liabilities	$1.64M	$2.51M	$3.07M	$3.89M
Total Debt	$7.31M	$6.67M	$5.93M	$176.00K
Total Liabilities	$8.41M	$8.55M	$8.28M	$10.12M
Retained Earnings	-$172.65M	-$189.56M	-$199.26M	-$204.21M
Shareholders' Equity	$14.92M	$3.03M	$6.77M	$3.93M
Working Capital	$8.41M	-$486.00K	$10.60M	$736.00K

XCUR Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$35.66M	-$10.36M	-$2.91M	-$8.55M
Capital Expenditure	-$10.00K	—	—	-$1.00K
Free Cash Flow	-$35.67M	-$10.36M	-$2.91M	-$8.56M
Depreciation & Amortisation	$1.86M	$1.38M	$824.00K	$460.00K
Stock-Based Compensation	$1.37M	$1.35M	$22.00K	$2.00K
Investing Cash Flow	$4.70M	-$1.08M	$0.00	-$1.81M
Financing Cash Flow	-$3.10M	$3.67M	$13.40M	$1.60M
Net Change in Cash	-$34.07M	-$7.76M	$10.49M	-$8.76M

XCUR Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$808.00K	$935.00K	$888.00K	$655.00K	$312.00K
Selling, General & Admin	$2.22M	$1.51M	$1.50M	$1.60M	$1.29M
Operating Expenses	$3.02M	$2.45M	$2.39M	$2.26M	$1.60M
Operating Income	-$3.02M	-$2.45M	-$2.39M	-$2.26M	-$1.60M
EBITDA	-$2.92M	-$2.32M	-$2.37M	-$3.37M	-$1.50M
Pretax Income	$3.01M	-$2.62M	-$2.44M	-$3.53M	-$1.83M
Income Tax	$0.00	$0.00	$0.00	-$634.00K	$0.00
Net Income	$3.01M	-$2.62M	-$2.44M	-$2.90M	-$1.83M
Diluted EPS	0.49	-0.41	-0.39	—	-0.29
Diluted Shares	6.18M	6.32M	6.32M	—	6.37M

XCUR Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$10.42M	$7.86M	$4.44M	$3.75M	$2.60M
Receivables	$172.00K	$77.00K	$55.00K	$58.00K	$60.00K
Current Assets	$11.30M	$8.65M	$5.44M	$4.62M	$3.53M
Total Assets	$20.68M	$18.74M	$15.27M	$14.04M	$12.76M
Current Liabilities	$3.89M	$4.57M	$2.77M	$3.89M	$4.46M
Total Debt	$619.00K	$476.00K	$366.00K	$176.00K	$22.00K
Total Liabilities	$9.30M	$9.88M	$8.34M	$10.12M	$10.66M
Retained Earnings	-$196.25M	-$198.88M	-$201.31M	-$204.21M	-$206.04M
Shareholders' Equity	$11.38M	$8.86M	$6.93M	$3.93M	$2.10M
Working Capital	$7.42M	$4.08M	$2.67M	$736.00K	-$928.00K

XCUR Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$1.60M	-$2.28M	-$3.53M	-$1.15M	-$1.14M
Free Cash Flow	-$1.60M	-$2.60M	-$3.42M	-$934.00K	-$1.14M
Depreciation & Amortisation	$108.00K	$128.00K	$67.00K	$157.00K	$106.00K
Stock-Based Compensation	$0.00	$1.00K	$0.00	$1.00K	—
Investing Cash Flow	-$2.09M	-$280.00K	$108.00K	$455.00K	$0.00
Financing Cash Flow	$1.60M	$0.00	$0.00	$0.00	$0.00
Net Change in Cash	-$2.09M	-$2.56M	-$3.42M	-$692.00K	-$1.14M

Market Snapshot

About

Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics based on its proprietary spherical nucleic acid (SNA) technology platform. The company's SNA constructs are designed to penetrate cells and tissues more effectively than traditional nucleic acid therapies, with applications in immuno-oncology, inflammatory diseases, and genetic disorders. Exicure is advancing multiple programs leveraging its novel nucleic acid architecture.